Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Cureus ; 14(7): e26500, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1975351

ABSTRACT

OBJECTIVE:  The coronavirus disease 2019 (COVID-19) pandemic disrupted all routine health care services and resulted in a significant reconfiguration of urologic cancer services and care pathways across the globe. This study aimed to retrospectively determine the pandemic's impact on the urologic oncological surgery outcomes at a high-volume referral center. MATERIALS AND METHODS: We compared the number and histopathological outcomes of urologic oncological procedures in a referral center coded during the pandemic and data of the period before the pandemic as control. Data were extracted from patient files and hospital records. The pathological examination included a complete histopathological staging according to TNM stage. RESULTS: A total of 683 patients were included in the study, 424 (62%) of which were operated in the pre-pandemic period. There was a 39% decline in urologic oncological surgical activity in the pandemic, mostly in renal and prostate cancer. The mean tumor size was larger in renal cancer patients who underwent surgery during the pandemic (5.6 cm vs 4.5 cm, p=0.002). During the pandemic, more lymph node involvement was seen after radical cystectomy and prostatectomy (50% vs 27.8%, p=0.024 and 12.5% vs 4.5%, p=0.026, respectively). No differences in terms of main pathologic features were observed in patients undergoing radical orchiectomy. CONCLUSION: COVID-19 appeared to adversely effect oncologic outcomes in patiens undergone surgery for prostate and bladder cancer. Tumor development induced by a delay in diagnosis may cause severe consequences for patients. Reprioritizion of non-deferrable urologic oncological seems crucial.

2.
Kardiochir Torakochirurgia Pol ; 19(2): 113, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1934495
3.
Heart Lung ; 50(2): 177, 2021.
Article in English | MEDLINE | ID: covidwho-1065103
4.
J Glob Antimicrob Resist ; 24: 106-107, 2021 03.
Article in English | MEDLINE | ID: covidwho-1028294

ABSTRACT

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is a positive-sense single-stranded RNA virus. As of today, no specific treatment has been found COVID-19. Intravenous immunoglobulin (IVIG) is a widely used therapy to prevent life-threatening infections in patients with primary and secondary immune deficiencies and autoimmune/inflammatory conditions. IVIG administration could be beneficial in the treatment of patients with severe COVID-19. In this respect, this presentation aimed to report a case of COVID-19 treated with IVIG.


Subject(s)
COVID-19 Drug Treatment , Immunoglobulins, Intravenous/therapeutic use , Antiviral Agents/therapeutic use , COVID-19/diagnostic imaging , COVID-19/immunology , Diabetes Mellitus, Type 2/immunology , Diabetes Mellitus, Type 2/virology , Humans , Immunologic Deficiency Syndromes/immunology , Immunologic Deficiency Syndromes/virology , Male , Middle Aged , SARS-CoV-2/isolation & purification
5.
J Allergy Clin Immunol Pract ; 9(1): 594, 2021 01.
Article in English | MEDLINE | ID: covidwho-799392
SELECTION OF CITATIONS
SEARCH DETAIL